Heart failure reflects impaired cardiac contractility and/or relaxation, resulting from myocardial infarction, hypertension, cardiomyopathy, or valvular disease. Progressive cardiomyocyte death, fibrotic remodelling, and neuroendocrine dysregulation drive the syndrome. Placental mesenchymal stem cells and their exosomes limit adverse remodelling by secreting anti-fibrotic factors (anti-TGF-β signalling), promoting angiogenesis (VEGF, FGF), enhancing cardiomyocyte survival (paracrine anti-apoptotic signals), and modulating inflammatory infiltration (reduced macrophage pro-inflammatory activation). One hundred twenty-four registered clinical trials and twelve actively recruiting sites explore intracoronary or intravenous MSC delivery in post-infarction left-ventricular dysfunction, dilated cardiomyopathy, and advanced heart failure awaiting transplantation.
Clinical trial data encompasses phase I–II safety documentation and phase II efficacy assessment across >3,000 treated patients globally. Representative studies report left-ventricular ejection fraction (LVEF) improvements of 5–10 percentage points (e.g., 25% → 35%) in 40–55% of treated cohorts over 6–12 months. Cardiac magnetic resonance imaging shows reduction in scar size and infarct zone wall thickness in responders. Exercise tolerance (6-minute walk distance, VO₂ max) improves modestly in 45–50%. Hospitalisation rates for acute decompensation decline by 25–40% in some cohorts over 12-month follow-up. Mortality benefit remains unproven in phase II; pivotal trials are ongoing.
Heart-failure stem-cell protocols in Sofia and international centres range €6,000–9,000 for treatment courses, typically incorporating 1–2 intracoronary or intravenous MSC infusions, baseline and serial cardiac imaging (echocardiography, cardiac MRI, coronary angiography), biomarker panels (BNP, troponin, inflammatory cytokines), and cardiology supervision. Catheterisation-lab facility fees and interventional cardiology expertise add substantially. Repeat treatment cycles incur cumulative costs; some protocols recommend re-dosing at 6–12 month intervals if functional decline recurs.
Cell therapy for Heart Failure & Cardiac Repair is offered as an individualised, physician-led programme. In the EU and US it is regulated as an advanced therapy rather than an approved 'cure' for this condition — it is currently investigational. That status is exactly why EU GMP oversight, characterised cells and honest evidence matter.
Most protocols involve one treatment visit with one or more infusions over a few days; some patients return for a second cycle. The exact plan — cell type, dose and route — is set only after a clinician reviews your records.
Eligibility depends on condition stage, age and overall health. A clinic should review your records before recommending anything and tell you honestly if you are not a good candidate. Our candidacy self-check gives an indicative read in 60 seconds.
An indicative Heart Failure & Cardiac Repair programme is €3,000–€8,000 for treatment (it varies by procedure). Add travel and hotel with our calculator for your true all-in cost — typically a fraction of US, UK or German pricing.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
← Back to Heart Failure & Cardiac Repair overview · Heart Failure & Cardiac Repair cost →
Médecine régénérative certifiée GMP au cœur de l'UE — à partir de 3 000–8 000 €, une fraction des prix américains ou allemands. Protocoles personnalisés pour patients de plus de 50 pays.
Évaluation médicale gratuite